Clinical trials: DME, open to volunteers
Diabetic Macular Edema
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)
- Trial name
- ELAAVATE (NCT06942520)
- Testing
- RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sierra Eye Associates
Diabetic Macular Edema (DME), Diabetic Retinopathy
Corticosteroid for Diabetic Macular Edema (DME) Study
Our current goals include confirming inflammation mediators are biomarkers of DR and DME The Aim of this project is to measure aqueous PGE2 and inflammatory cytokines before and after treatment of DME with intravitreal…
- Trial name
- NCT07843849
- Testing
- Intravitreal dexamethasone implant
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
The purpose of this study is to evaluate the safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of multiple doses of RO7823653 in participants with DME, administered by intravitreal (IVT) injection as…
- Trial name
- NCT07425522
- Testing
- RO7823653, Faricimab
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Genentech, Inc.
Diabetic Macular Edema, DME
A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.
- Trial name
- NCT07199777
- Testing
- SNP318
- Volunteers
- 60 people
- Sponsor
- SciNeuro
Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues.
- Trial name
- NCT06662994
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Retina Consultants of Orange County
Diabetic Macular Edema (DME)
Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)
The goal of this clinical trial is to understand whether Zhuochuming® (Aflibercept Intravitreal Injection) using a 3 loading doses followed by a treat-and-extend regimen (3+T\&E) can treat patients with diabetic macular edema…
- Trial name
- NCT07612904
- Testing
- Aflibercept Intravitreous Injection
- Where
- China
- Volunteers
- 186 people
- Sponsor
- The Third Peoples Hospital of Dalian
Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
Diabetes mellitus is a disorder of sugar and fat metabolism which results in damage to the small blood vessels in various organs, this includes the retina - the part of the eye that processes light into a nerve impulse.
- Conditions
- Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus, Diabetic Macular Edema (DME)
- Trial name
- IMLADRIS (NCT06914778)
- Testing
- Blood draw for the laboratory assessment, Urine sample
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hywel Dda Health Board
Early OCT Biomarker Changes in Response to Anti-VEGF
Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME
A retrospective, observational, hospital-based study which will be conducted in the Department of Ophthalmology, Sohag University Hospital, Egypt.
- Trial name
- NCT06841250
- Testing
- intravitreal injection of anti-VEGF
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Diabetic Macular Edema, Macular Edema
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema
- Trial name
- NCT04187443
- Testing
- MS-553
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Diabetic Macular Edema, Visual Impairment
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these…
- Conditions
- Diabetic Macular Edema, Visual Impairment, Diabetes Mellitus, Hyperglycaemia (Diabetic)
- Trial name
- BiomarkerOCT (NCT06984822)
- Testing
- Anti-VEGF treatment, Dexamethasone implant, Treatment with intravitreal anti-VEGF OR Dexamethasone implant
- Where
- 2 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Vastra Gotaland Region
Diabetic Macular Edema (DME)
Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
Diabetic macular edema is a frequent complication of long-standing diabetes mellitus in which fluid leaks into the central part of the retina (macula), leading to reduced vision.
- Trial name
- NCT07338097
- Testing
- Aflibercept (2.0 mg), Bevacizumab
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- CMH Multan Institute of Medical Sciences
Deep Margin Elevation, Pulpal and Periodontal Health
Impact of DME on Pulpal and Periodontal Health at Varying Gingival Seat Level
The classical idea was to keep the biologic width untouched in order to maintain periodontal health but the newer case reports have given a new dimension to this concept, stating that a limited extension into STA can be used as…
- Trial name
- NCT07169305
- Testing
- Deep Margin Elevation
- Where
- India
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Diabetic Macular Edema
Kamuvudine-9 (K9) in Diabetic Macular Edema
The objectives of this investigation are to assess: 1. whether oral K9 is safe in subjects with DME, and 2. whether oral K9 improves BCVA compared to oral placebo
- Trial name
- K9 (NCT07458061)
- Testing
- Kamuvudine K9
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dr. Bryan Strelow
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705555
- Testing
- MK-8748, Aflibercept
- Where
- 33 sites in United States, Argentina and 2 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Retinopathy
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina).
- Trial name
- NAAVIGATE (NCT07592273)
- Testing
- Surabgene Lomparvovec, Topical Steroid, Artificial Tears
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 576 people
- Sponsor
- AbbVie
Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME)
Study of JMKX003948 Ophthalmic Suspension in Healthy Participants
The study is a randomized, double-blind, placebo-controlled, phase 1 study of JMKX003948 Ophthalmic Suspension to evaluate the safety, tolerability and PK of single and multiple ascending doses in healthy participants.
- Trial name
- NCT06832657
- Testing
- JMKX003948 Ophthalmic Suspension
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jemincare
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- ATACAMA (NCT07841899)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- GOBI (NCT07842016)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Deep Marginal Elevation, Periodontal Microenvironment
Deep Marginal Elevation and the Periodontal Microenvironment ( DME-PM )
This study aims to evaluate the impact of the dental restorative procedure known as Deep Marginal Elevation (DME) on periodontal health, including gingival and bone status, in patients with deep dental caries.
- Conditions
- Deep Marginal Elevation, Periodontal Microenvironment, Microbiological Study, Clinical Study
- Trial name
- NCT07156695
- Testing
- Deep Marginal Elevation (DME)
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Tanta University
Diabetic Macular Edema (DME)
Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients
This is a 12-month, prospective, randomized controlled, multi-center, open-label, superiority designed study. Treatment-Naïve DME patient with inflammatory biomarkers, who meet the inclusion and exclusion criteria, will be…
- Trial name
- DECADE (NCT07438119)
- Testing
- Combination Therapy with Aflibercept Intravitreous Injection (2mg) and Dexamethasone Intravitreal Implant, Aflibercept Intravitreous Injection (2mg) Monotherapy
- Volunteers
- 114 people
- Sponsor
- Kun Liu